PT-141 (Bremelanotide): Mechanisms & Research
PT-141, or bremelanotide, is a cyclic melanocortin-receptor agonist. The registered U.S. product Vyleesi was approved in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women under its specific label. That approval does not apply to a research-grade PT-141 vial.
This article distinguishes receptor pharmacology from the measured clinical endpoints and summarizes the registered formulation’s PK. It does not assume that other melanocortin agonists’ shock or brain-injury findings belong to bremelanotide.
What is PT-141?
Bremelanotide is a cyclic heptapeptide from the melanotan medicinal-chemistry lineage. The Vyleesi label describes activity at several melanocortin receptors, with MC1R and MC4R relevant to the proposed pharmacology. The mechanism of improvement in HSDD is not fully established.
It is a different molecule and formulation from Melanotan II. A relative receptor or pigmentation claim should be tied to an actual comparative assay rather than inferred from which compound obtained approval.
Mechanism of Action
Melanocortin signaling is distinct from PDE5 inhibition, but that distinction does not prove a complete clinical mechanism or eliminate blood-pressure effects.
Melanocortin Receptor Signaling
The label describes receptor agonism, but states that the mechanism by which bremelanotide improves HSDD is unknown. Proposed central MC4R pathways should be identified as mechanistic interpretation, rather than established explanations for every clinical response.
Different From PDE5 Inhibition
Bremelanotide is not a PDE5 inhibitor. Clinical findings in HSDD measure desire and related distress in the enrolled population; they are not evidence of universal erectile-function rescue, enhanced performance or independence from all peripheral physiology.
Do Not Generalize From Other Agonists
MC1R activity is relevant to pigmentation. Findings for another melanocortin agonist cannot be transferred solely because the compounds share a receptor class.
Pharmacokinetics
For the registered subcutaneous Vyleesi formulation, the label reports a mean terminal half-life of 2.7 hours (range 1.9–4.0 hours) and a median time to maximum concentration of about one hour. Bremelanotide is metabolized by hydrolysis of amide bonds, rather than a demonstrated primarily hepatic-clearance mechanism. Radiolabel recovery was approximately 64.8% in urine and 22.8% in feces.
These values describe the tested clinical formulation and population. They do not establish exposure for an arbitrary research vial, oral formulation or another melanocortin peptide.
Clinical and Research History
The two RECONNECT randomized, placebo-controlled phase 3 trials reported improvements in sexual-desire and related-distress measures in premenopausal women with HSDD. They did not show a significant between-group improvement in the number of satisfying sexual events. The 2019 primary report is by Kingsberg et al.
Vyleesi’s FDA approval concerns its labelled indication and pharmaceutical formulation. A study or approval for that product does not certify the identity, content, sterility or safety of a separately supplied PT-141 powder.
Safety Considerations
The bremelanotide safety profile is well characterized from the Vyleesi registration program. The most commonly reported adverse events in the Phase III trials were nausea (the most frequent reason for discontinuation), flushing, injection-site reactions, and headache. Two cardiovascular signals warrant specific note.
First, bremelanotide produces a transient increase in blood pressure and decrease in heart rate in the hours following administration; the labeling carries a contraindication for uncontrolled hypertension and known cardiovascular disease. Second, focal hyperpigmentation of the face, gums, and breasts has been reported with repeated dosing, attributable to MC1R activity; it is more common at higher cumulative exposure and is dose-related. These are factual safety observations from the registered clinical record, not editorial commentary. Researchers should design protocols around the published exposure profile and review storage and handling guidance in our storage reference.
Conclusion
Bremelanotide has a registered formulation and randomized HSDD evidence with defined endpoints. That clinical record should be described precisely: receptor agonism does not supply a complete proven mechanism, and the Vyleesi approval is not a quality or safety authorization for research-grade PT-141.
Source this peptide for your research
Order PT-141 at Baltic PeptidesResearch source
Source PT-141 (Bremelanotide) for your research
Compare available sizes and check the matching batch certificate before ordering.
View productFrequently Asked Questions
Is PT-141 the same as Melanotan II?
PT-141/bremelanotide and Melanotan II are different cyclic peptides from the same development lineage. The Vyleesi label and MT2 pilot describe different products and evidence. Approval of one does not validate the other or establish an unmeasured comparative receptor-selectivity claim.
Is PT-141 orally active?
Vyleesi is a subcutaneous product, and early development also evaluated intranasal delivery. The registered label does not establish an approved oral formulation; the absence of one should not be turned into an absolute statement that no oral experimental exposure is possible.
What is the FDA approval status of bremelanotide?
The FDA approved Vyleesi in 2019 for its specific labelled HSDD indication. The approval applies to the pharmaceutical product, not research-grade PT-141 powder. Off-label clinical prescribing and the use of an unapproved research preparation are separate regulatory questions.
Does PT-141 cause hyperpigmentation?
The Vyleesi label notes focal hyperpigmentation of the face, gums, and breasts as a reported adverse event with repeated dosing, attributable to MC1R activity. The frequency is higher at higher cumulative exposure. This is a factual entry in the registered safety record and is one of the reasons for the as-needed (rather than daily) dosing pattern.
What purity standard should research-grade PT-141 meet?
Review the lot-specific report for the exact sequence, modifications, HPLC method/trace and interpreted MS result. A compatible intact mass supports composition but is not complete sequence confirmation. If stock concentration matters, obtain a quantitative target-content basis; HPLC area purity is separate from net content. Select acceptance criteria for the model rather than assuming one percentage measures every quality attribute.
Scientific References
- DailyMed. Vyleesi prescribing information: indication, pharmacology, PK and safety - Primary source
- Kingsberg et al. 2019. Two RECONNECT randomized phase 3 trials. PMID: 31599840 - Primary source[PubMed Reference]
Related Research Peptides
PT-141 (Bremelanotide)
Melanotan II
